Implantable medical device with integrated acoustic transducer

Information

  • Patent Grant
  • 7522962
  • Patent Number
    7,522,962
  • Date Filed
    Friday, December 2, 2005
    18 years ago
  • Date Issued
    Tuesday, April 21, 2009
    15 years ago
Abstract
An implantable medical device comprises a hermetically sealed housing having at least one hermetic electrical feed through and an acoustic lead having a proximal end connected to the electrical feed through. One or more acoustic transducers are carried in a distal portion of the acoustic lead and configured for converting energy between electrical energy and acoustic energy, wherein electronics for driving the one or more transducers are carried in the housing.
Description
FIELD OF INVENTION

The present invention relates to the field of diagnostic and therapeutic medical implants and data communication between them.


BACKGROUND

Communication between diagnostic and/or therapeutic medical device implants within the body can be highly beneficial. One example is the information exchange between an implantable sensor and an implantable pulse generator (IPG), that uses the sensed information for optimizing its operation. Published U.S. Patent Application US 2004-0204744A1, which is incorporated by reference herein, discloses using an intra-body acoustic communication link for this purpose. As taught in that publication, in order to minimize energy consumption, the sensor implant is left deactivated (i.e., not powered on) until an acoustic wave pulse received from another implanted device activates the sensor implant using acoustic switch technology. Two possible transducer configurations applicable for this concept are disclosed in this published application.


Acoustic transducers integrated in implantable medical device are known. For example, U.S. Pat. No. 6,477,406, discloses several acoustic transducer configurations used for listening to sounds produced by the heart. However, these transducers were designed only for receiving acoustic signals, and not for transmitting acoustic signals. Moreover, the transducer configurations of this patent are optimized to low sound frequencies in a range of 5-300 Hz, while for acoustic communication much higher frequencies are used, e.g., in an ultrasonic range of 20 kHz-10 MHz. In particular, U.S. Pat. No. 6,477,406 does not teach an acoustic transducer that can effectively produce ultrasonic transmission or to serve as an effective receiver at high acoustic frequencies.


Acoustic communication was also suggested for data exchange between an implantable device and external unit, such as disclosed in U.S. Pat. No. 5,113,859. However, this patent also does not teach or describe an acoustic transducer capable of performing the communication, nor is there any transducer disclosed or described that is capable of transmitting ultrasonic signals at a level sufficient for activating an acoustic switch and or communicating with a second implant.





BRIEF DESCRIPTION OF THE DRAWINGS

The drawings illustrate the design and utility of embodiments of the invention, in which similar elements are referred to by common reference numerals. With the understanding that these drawings depict only exemplary embodiments of the invention, and are not therefore to be considered limiting its scope, the embodiments will be described and explained with additional specificity and detail through the use of the accompanying drawings, in which:



FIG. 1 depicts an exemplary embodiment of an acoustic transducer integrated on an end of an implantable acoustic lead.



FIGS. 2, 2a, 2b and 2c depict alternate embodiments of an acoustic transducer integrated on an end of an implantable acoustic lead.



FIGS. 3
a and 3b illustrate still further alternate embodiments of an acoustic transducer integrated on an end of an implantable acoustic lead, in which the transducer is based on a piezoelectric ceramic bar coupled to a flat surface acting as a membrane.





DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS

The present invention is directed to an (active) implantable medical device such as a pacemaker, implantable cardioverter defibrillator (ICD), Cardiac Rhythm Therapy (CRT), a standalone hemodynamic monitor, or implantable drug pump, which communicates with another implanted device (not shown), or an extracorporeal device (not shown), using an acoustic communication link. Towards this end, the active implantable device is provided with an acoustic transducer capable of transmitting an acoustic pulse sufficient for activating an acoustic switch in the receiving device, such as described in U.S. Pat. No. 6,628,989. For this purpose, an acoustic pulse that is at least 0.1 msec wide, and at least a 50 Pa peak pressure is preferred. For example, a pulse of 0.5 msec and 500 Pa may be used in one embodiment. The acoustic transducer is preferably capable of transmitting acoustic pulses at a pressure of at least 0.05 Pa (measured at 20 cm in vitro) and receiving signals of 0.05 Pa. The frequency range at which the system can operate is preferably within a range of 20 KHz-3 MHz. In order to maximize the efficiency of the transducer, it is preferably designed to operate at its resonance frequency.


The acoustic transducer may be constructed on an internal surface of the implantable device housing, typically a hermetically sealed enclosure, with a portion of the enclosure housing wall coupled to the transducer and acting as a vibrating diaphragm. Several examples of such embodiments are disclosed and described in co-pending U.S. patent application Ser. No. 11/287,557, filed Nov. 23, 2005, entitled “Implantable Medical Device With Integrated Acoustic Transducer,” the disclosure of which is hereby incorporated by reference in its entirety.


Integrating the acoustic transducer within the medical device enclosure is practically transparent to the implanting physician. Also in this configuration the hermetic enclosure protects the transducer and its electronics from the environment. However, usually the implantation location of the active medical device is limited due to its size and the wish to minimize the implantation procedure invasiveness. As a result the implantation site can be sub-optimal for acoustic communication. For example, an IPG is most often implanted under the skin beneath the collar bone. Due to anatomy and the physical fact that acoustic waves can not cross the lungs any communication between the IPG and a second implant located within the heart may be sub-optimal.



FIG. 1 illustrates one embodiment of the invention, in which the linkage between the location of an IPG and that of the transducer is disconnected. In particular, an acoustic transducer is located at the tip of a lead 300, referred to herein as an “acoustic lead.” The acoustic lead 300 can be similar to an electrical lead commonly used in IPGs (e.g., for pacing). In a preferred embodiment, the acoustic lead 300 is not positioned within the heart, but rather in a vein leading to the right atrium, e.g. the subclavian vein, the cephalic vein, the right or left brachiocephalic vein, the superior or inferior vena cava or the internal jugular vein. The connection of the said acoustic lead 300 to an IPG 305 can be via a standard electrical hermetic feed through 303 of the IPG 305.


Implantation of the acoustic lead 300 can be performed using the same catheterization techniques used for implanting IPG electrical leads. However, instead of entering the right atrium (and in some cases the heart right ventricle), the acoustic lead can preferably be located external to the heart, and preferably in a location with a direct “line of sight” between the lead acoustic source and a second implant to be in communication with the transducer. Many of the risks involved in implanting an IPG electrical lead, such as thrombus formation or damage to the heat valve, may be avoided by not entering the heart or passing through the heart valve. The fixation of the acoustic lead 300 may be accomplished, for example, by a radial anchoring of the device to a wall of the vessel using a stent-like device, or with a screw or hook-type fixation to the vessel wall.


Alternatively the lead can be implanted at other positions not via catheterization, for example under the skin, or taking advantage of the cut required for implanting the IPG, the lead can be positioned in the cut and aligned optimally to the implant in order to optimize the acoustic channel. The connection of the said acoustic lead to the IPG can be via a standard electrical feed through of the IPG. The implantation of the acoustic lead can be using the same technique of catheterization used for implanting IPG electrical leads. However, preferably instead of entering the right atrium and in some cases the heart right ventricle, the acoustic lead can be located external to the heart, preferably in a location with a direct line of sight between the lead acoustic source and the second implant. Many of the risks involved in implanting an IPG electrical lead, such as thrombus formation or damage to the heat valve, may be avoided by not entering the heart or passing through the heart valve.


The transducer in FIG. 1 is based on the design disclosed in U.S. Pat. No. 6,140,740, the contents of which are fully incorporated herein by reference. The transducer may be manifested as a single transducer or as an array of such transducers, used mainly for transforming acoustic energy into electrical energy. The transducer(s) generally include (i) a cell member having a cavity; (ii) a substantially flexible piezoelectric layer attached to the cell member, the piezoelectric layer having an external surface and an internal surface, the piezoelectric layer featuring such dimensions so as to enable fluctuations thereof at its resonance frequency upon impinging of the acoustic interrogation signal; and (iii) a first electrode attached to the external surface and a second electrode attached to the internal surface.


The piezoelectric layer is preferably of a material selected from the group consisting of PVDF and piezoceramic. A transducer based on this design can produce approximately 100 Pa for 100 volts of excitation voltage. Since the transducer is made of a PVDF or a similar material, it can withstand much higher voltages. As a result, the transmission acoustic requirements for activating an acoustic pulse can be easily met with such a transducer at a voltage of several hundreds of volts. The high voltage required can be produced in the IPG or more preferably close to the transducer using a transformer of similar step up voltage device known in the art.



FIGS. 2 & 2
a disclose alternative transducer designs that can substantially reduce the high voltage requirement of the transducer design proposed in FIG. 1. The design is based on providing an array of transducers, such as the transducer of FIG. 1. Several such transducers may be connected in parallel in order to increase the transmitted pressure. Since each of the proposed transducer is relatively small (about 2 mm in diameter), several such transducers can be integrated into a lead of less than 12 Fr, or even less than 8 Fr. with minimal compromising on the lead flexibility.


The array can be single sided, as shown in FIG. 2, or double sided as shown in FIG. 2a. Since the proposed transducer thickness is about 1 mm or less, other configurations are possible in which bars of transducer array are assembled together forming geometric form of a triangle (FIG. 2b), or a square (FIG. 2c), or other forms such as a pentagon, hexagon or even more complex configurations. The specific number of acoustic cell members on each face (4 are shown) may vary in a range between 1-20 cells per face. These proposed array assemblies have the advantage of increasing the number of acoustic cells while retaining a low lead diameter. Since the connection between the acoustic cell members can be flexible the resulted lead can also be highly flexible.


Since the physical behavior of an array of transducers may vary from that of the single transducer due to the mutual effect imposed by the neighboring cells, the cell members in the array may be connected in parallel to the same driver or may have separate power sources which have different phases and/or voltage amplitude for optimizing the transmitted acoustic pulse. Also, each of the acoustic cell members can have different acoustic response characteristics, e.g. resonance frequency and resonance width, so as to optimize the acoustic response for the specific application.



FIGS. 3
a and 3b illustrate a transducer that is based on a piezoelectric ceramic bar coupled to a flat surface acting as a membrane. The length of the structure is fixed by a rigid backbone, whereas preferably the entire structure is vibrating at its resonance frequency. FIG. 3a discloses such an acoustic transducer structure in which a piezoelectric bar (220) (alternatively built from pieces of ceramic) is coupled to the internal diaphragm (230), preferably a metallic one. A means for fixing the length of the structure should be implanted such as the proposed bar (240) in FIG. 3a. An additional configuration of such a transducer is disclosed in FIG. 3b. This design has two transducers, which are based on the design suggested in FIG. 3a. In this design the fixation bar (240) is in the center of the structure.


It will be appreciated that the illustrated embodiments are by way of example, and not limitation, and other and further transducer embodiments may be employed within the scope of the inventions disclosed herein.


Piezoelectric materials are well known and the proposed design of the transducer can use any material from the group including: electrostrictive ceramic, piezoelectric ceramic, piezoelectric ceramic-polymer composite and piezoelectric polymers. The proposed transducer design can employ one or more piezoelectric discs with an electrode there between discs, e.g., two discs surrounding an electrode. This configuration allows for electrical connection of the piezoelectric discs in series, in parallel, or in a combination of the two, using electrical contacts to the disc electrodes. This configuration allows optimization of the transducer for specific tasks. For example, the voltage available in an IPG is usually relatively low, produced from its internal 2-3 volts battery. For transmitting an acoustic signal required for activating an acoustic switch, a relatively high voltage may be required (for example, several hundred volts).


Using multiple, thin discs of piezoelectric material connected in parallel will produce the equivalent acoustic power of a single, thicker disc, but at a substantially lower voltage. For example, two piezoelectric discs that are each 0.5 mm thick, connected in parallel, will produce a similar acoustic power as a 1 mm thick piezoelectric disc at half the voltage. However, if one wishes to optimize the receiving sensitivity of the transducer, serial connection of the thin piezoelectric discs will result in a higher voltage signal per a given acoustic signal, than a single thick disk. The ceramics may also be connected anti-parallel, to produce a bending moment as a piezoelectric bimorph.


For producing the transmitted acoustic signal, the proposed acoustic transducer should be efficient and durable. Preferably, the transducers should work at their resonance frequency in order to optimize the efficiency and sensitivity of the transducer. The resonance frequency of the transducer depends on several parameters, including the type, thickness and diameter of the piezoelectric material, the material and thickness of the diaphragm (230), and the material, thickness, and height of the rigid wall 240, as is known by those skilled in the art of acoustic transducer design.


For optimizing the receiving sensitivity of the transducer, a separate piece of piezoelectric material with relatively high acoustic sensitivity can be used, such as a layer of PVDF (not shown), attached to the piezoelectric ceramic disc/s used for transmission. Another way to improve the receiving signal to noise is by integrating an amplifier close to the structure or within the lead in order to minimize any parasitic effects and noises.


All the above-disclosed, implantable transducers can, in addition to activation and communication with a second implant, also be used for acoustically energizing and charging the second implant. Preferably, the acoustic lead design of FIG. 1 should be used for this purpose, taking advantage of the optimized location of the transducer in these configurations relative to the second implant. The possible line of sight between the lead transducer and the second implant, combined with the possible small distance between them, which can be between a few millimeters to several centimeters, can significantly reduce the required energy for charging the second implant battery or capacitor. The charging can be done using energy from the IPG battery, or from an extracorporal power source (either telemetrically, or by making a small incision at the IPG implantation site), disengaging the acoustic lead from the IPG controller, connecting the acoustic lead to an external power source, and using the acoustic energy produced by the acoustic lead to charge the battery within the second implant.


Preferably, the battery capacity of the second implant is such that charging will not be required for a duration longer than that of the IPG battery. Upon the replacement of the IPG controller, the acoustic lead can be connected to an external power source for charging the second implant battery. Alternatively, an acoustic catheter can be used for acoustically charging the second implant. This catheter can be built similar to the acoustic lead, with an acoustic transducer at its tip or by serving as an acoustic wave-guide. The acoustic catheter can be introduced to the body in a similar technique used for right heart catheterization. This procedure is usually carried out via the femoral vein and internal jugular subclavian vein, using a standard guide wire based catheterization or by a floating balloon (e.g., a Swan-Ganz catheter). The procedure can be guided using fluoroscopy or pressure pattern measurements. Since the acoustic source on the catheter can be located very close to the second implant, the charging process is preferably very efficient and local.


The transducer designs disclosed herein are preferably encapsulated as required for an implantable active medical device. Methods of manufacturing electrical leads for IPG are well known in the art, and one may use such known methods, and materials such as polyurethane or silicone extrusion, for encapsulating the transducer and its supporting electronics. Alternatively, the transducer may be encapsulated in a metallic sealed case filled with inert liquid (e.g. silicone oil) and having at least one flexible face. Such a metallic box can be made from any biocompatible metal such as titanium, tantalum, stainless steel, gold or platinum with a flexible membrane preferably less the 0.5 mm thick and more preferably less than 0.05 mm thick.

Claims
  • 1. An implantable medical device, comprising: a hermetically sealed housing having at least one hermetic electrical feed through;an acoustic lead having a proximal end connected to the electrical feed through;one or more acoustic transducers carried in a distal portion of the acoustic lead and configured for converting energy between electrical energy and acoustic energy; andelectronics carried in the housing for driving the one or more transducers.
  • 2. The device of claim 1, wherein the one or more transducers are further configured for acoustic communication with another implantable medical device.
  • 3. The device claim 1, the one or more transducers comprising: a diaphragm having a width, thickness and length, a piezoelectric material having a rectangular shape coupled to said diaphragm,means for keeping the length of the diaphragm substantially unchanged, andmeans for electrically activating the piezoelectric material in order to induce movement of the diaphragm.
  • 4. The device of claim 3, wherein the diaphragm comprises a metal having a thickness of approximately 0.1 mm to 5 mm.
  • 5. The device of claim 3, wherein the diaphragm comprises a metal having a width of approximately 0.4 mm to 8 mm.
  • 6. The device of claim 3, wherein the diaphragm comprises a metal having a length of 0.5 mm to 25 mm.
  • 7. The device of claim 3, wherein the piezoelectric material has a thickness of between 0.05 mm to 5 mm.
  • 8. The device of claim 3, wherein the piezoelectric material has a width of between 0.3 mm to 8 mm.
  • 9. The device of claim 3, wherein the piezoelectric material has a length of between 0.05 mm to 25 mm.
  • 10. The device of claim 1, wherein the one or more transducers comprises an array of transducers.
  • 11. The device of claim 1, wherein the distal portion of the acoustic lead comprises a bar, and wherein the one or more acoustic transducers comprises a single acoustic transducer.
  • 12. The device of claim 1, wherein the distal portion of the acoustic lead comprises a bar, and wherein the one or more acoustic transducers comprises an array of transducers.
  • 13. The device of claim 12, wherein the array of transducers is a single-side array of transducers.
  • 14. The device of claim 12, wherein the array of transducers is a double-sided array of transducers.
  • 15. The device of claim 1, wherein the distal portion of the acoustic lead comprises a plurality of bars each including one or more acoustic transducers.
  • 16. The device of claim 15, wherein the plurality of bars form a triangular-shaped structure.
  • 17. The device of claim 15, wherein the plurality of bars form a square-shaped structure.
  • 18. The device of claim 1, wherein the one or more acoustic transducers includes at least one piezoelectric bar coupled to a membrane.
  • 19. An implantable medical device, comprising: a hermetically sealed housing having at least one hermetic electrical feedthrough;an acoustic lead having a proximal portion coupled to the electrical feedthrough;a plurality of acoustic transducers each carried in a distal portion of the acoustic lead and configured for converting energy between electrical energy and acoustic energy; andelectronics carried in the housing for driving the one or more transducers.
  • 20. An implantable medical device, comprising: a hermetically sealed housing having at least one hermetic electrical feedthrough;an acoustic lead having a proximal portion connected to the electrical feedthrough;one or more acoustic transducers carried in a distal portion of the acoustic lead and configured for converting energy between electrical energy and acoustic energy, the one or more transducers including a piezoelectric material coupled to a diaphragm, a means for keeping the length of the diaphragm substantially unchanged, and a means for electrically activating the piezoelectric material in order to induce movement of the diaphragm; andelectronics carried in the housing for driving the one or more transducers.
RELATED APPLICATION DATA

The present application claims the benefit of priority under 35 U.S.C § 119 to U.S. Provisional Application 60/633,063, filed Dec. 3, 2004, the contents of which are hereby incorporated by reference.

US Referenced Citations (159)
Number Name Date Kind
2967957 Massa Jan 1961 A
3568661 Franklin Mar 1971 A
3676720 Libby et al. Jul 1972 A
3757770 Brayshaw et al. Sep 1973 A
3792204 Murayama et al. Feb 1974 A
3798473 Murayama et al. Mar 1974 A
3832580 Yamamuro et al. Aug 1974 A
3894198 Murayama et al. Jul 1975 A
3940637 Ohigashi et al. Feb 1976 A
3978353 Kinoshita Aug 1976 A
4008408 Kodama Feb 1977 A
4051455 Fowler Sep 1977 A
4056742 Massa Nov 1977 A
4064375 Russell et al. Dec 1977 A
4096756 Alphonse Jun 1978 A
4127110 Bullara Nov 1978 A
4170742 Itagaki et al. Oct 1979 A
4181864 Etzold Jan 1980 A
4227407 Drost Oct 1980 A
4281484 Massa Aug 1981 A
4431873 Dunn et al. Feb 1984 A
4433400 De Reggi et al. Feb 1984 A
4456850 Inoue et al. Jun 1984 A
4481950 Duggan Nov 1984 A
4517665 De Reggi et al. May 1985 A
4519401 Ko et al. May 1985 A
4541431 Ibrahim et al. Sep 1985 A
4558249 Lerch et al. Dec 1985 A
4580074 Gilman Apr 1986 A
4593703 Cosman Jun 1986 A
4600855 Strachan Jul 1986 A
4642508 Suzuki et al. Feb 1987 A
4653036 Harris et al. Mar 1987 A
4653508 Cosman Mar 1987 A
4660568 Cosman Apr 1987 A
4672976 Kroll Jun 1987 A
4676255 Cosman Jun 1987 A
4677337 Kleinschmidt et al. Jun 1987 A
4781715 Wurzel Nov 1988 A
4793825 Benjamin et al. Dec 1988 A
4835435 Yeung et al. May 1989 A
4846191 Brockway et al. Jul 1989 A
4911172 Bui et al. Mar 1990 A
4958100 Crawley et al. Sep 1990 A
5012815 Bennett, Jr. et al. May 1991 A
5024224 Engebretson Jun 1991 A
5088576 Potthoff et al. Feb 1992 A
5113859 Funke May 1992 A
5160870 Carson et al. Nov 1992 A
5178153 Einzig Jan 1993 A
5283397 Pavlovic Feb 1994 A
5289821 Swartz Mar 1994 A
5300875 Tuttle Apr 1994 A
5314457 Jeutter et al. May 1994 A
5339290 Greenstein Aug 1994 A
5367500 Ng Nov 1994 A
5381067 Greenstein et al. Jan 1995 A
5381386 Lum et al. Jan 1995 A
5410587 Grunwell Apr 1995 A
5411551 Winston et al. May 1995 A
5423334 Jordan Jun 1995 A
5438553 Wilson et al. Aug 1995 A
5476488 Morgan et al. Dec 1995 A
5483501 Park et al. Jan 1996 A
5488954 Sleva et al. Feb 1996 A
5495137 Park et al. Feb 1996 A
5554177 Kieval et al. Sep 1996 A
5562714 Grevious Oct 1996 A
5571152 Chen et al. Nov 1996 A
5628782 Myers May 1997 A
5679026 Fain et al. Oct 1997 A
5704352 Tremblay et al. Jan 1998 A
5733313 Barreras, Sr. et al. Mar 1998 A
5735887 Barreras, Sr. et al. Apr 1998 A
5741316 Chen et al. Apr 1998 A
5749909 Schroeppel et al. May 1998 A
5757104 Getman et al. May 1998 A
5792195 Carlson et al. Aug 1998 A
5807258 Cimochowski et al. Sep 1998 A
5825117 Ossmann et al. Oct 1998 A
5832924 Archibald et al. Nov 1998 A
5833603 Kovacs et al. Nov 1998 A
5843135 Weijand et al. Dec 1998 A
5873835 Hastings et al. Feb 1999 A
5879283 Adams et al. Mar 1999 A
5935081 Kadhiresan Aug 1999 A
5956292 Bernstein Sep 1999 A
5957950 Mockros et al. Sep 1999 A
5967986 Cimochowski et al. Oct 1999 A
6044298 Salo et al. Mar 2000 A
6053873 Govari et al. Apr 2000 A
6058329 Salo et al. May 2000 A
6068589 Neukermans May 2000 A
6082367 Greeninger et al. Jul 2000 A
6140740 Porat et al. Oct 2000 A
6141588 Cox et al. Oct 2000 A
6185452 Schulman et al. Feb 2001 B1
6223081 Kerver Apr 2001 B1
6409675 Turcott Jun 2002 B1
6475170 Doron et al. Nov 2002 B1
6477406 Turcott Nov 2002 B1
6480733 Turcott Nov 2002 B1
6486588 Doron et al. Nov 2002 B2
6504289 Toda et al. Jan 2003 B2
6527729 Turcott Mar 2003 B1
6537200 Leysieffer et al. Mar 2003 B2
6554761 Puria et al. Apr 2003 B1
6575894 Leysieffer et al. Jun 2003 B2
6600949 Turcott Jul 2003 B1
6628989 Penner et al. Sep 2003 B1
6629922 Puria et al. Oct 2003 B1
6643548 Mai et al. Nov 2003 B1
6645145 Dreschel et al. Nov 2003 B1
6654638 Sweeney Nov 2003 B1
6671550 Iaizzo et al. Dec 2003 B2
6697674 Leysieffer Feb 2004 B2
6740076 Hoben et al. May 2004 B2
6741714 Jensen May 2004 B2
6763722 Fjield et al. Jul 2004 B2
6764446 Wolinsky et al. Jul 2004 B2
6772490 Toda Aug 2004 B2
6792308 Corbucci Sep 2004 B2
7016739 Bange et al. Mar 2006 B2
7024248 Penner et al. Apr 2006 B2
7035684 Lee Apr 2006 B2
7107103 Schulman et al. Sep 2006 B2
7114502 Schulman et al. Oct 2006 B2
7115096 Siejko et al. Oct 2006 B2
7118531 Krill Oct 2006 B2
7123962 Siejko et al. Oct 2006 B2
7127290 Girouard et al. Oct 2006 B2
7176602 Schlenke Feb 2007 B2
7198603 Penner et al. Apr 2007 B2
7220232 Suorsa et al. May 2007 B2
7228175 Jain et al. Jun 2007 B2
7236821 Cates Jun 2007 B2
7248923 Maile et al. Jul 2007 B2
7260429 Siejko et al. Aug 2007 B2
7273457 Penner Sep 2007 B2
7283874 Penner Oct 2007 B2
7335169 Thompson et al. Feb 2008 B2
7431699 Siejko et al. Oct 2008 B2
20040106954 Whitehurst et al. Jun 2004 A1
20040122484 Hatlestad et al. Jun 2004 A1
20040127792 Siejko et al. Jul 2004 A1
20040138572 Thiagarajan Jul 2004 A1
20040204744 Penner et al. Oct 2004 A1
20040230249 Haefner Nov 2004 A1
20050131472 Ding et al. Jun 2005 A1
20050137490 Scheiner et al. Jun 2005 A1
20050149138 Min et al. Jul 2005 A1
20060009818 Von Arx et al. Jan 2006 A1
20060142819 Penner et al. Jun 2006 A1
20060149329 Penner Jul 2006 A1
20070049977 Von Arx et al. Mar 2007 A1
20070142728 Penner et al. Jun 2007 A1
20080021289 Zhang et al. Jan 2008 A1
20080021509 Mi et al. Jan 2008 A1
20080021510 Mi et al. Jan 2008 A1
Foreign Referenced Citations (17)
Number Date Country
3222349 Jan 1984 DE
0798016 Oct 1997 EP
0897690 Feb 1999 EP
1151719 Nov 2001 EP
WO 8303345 Oct 1983 WO
WO 9701986 Jan 1997 WO
WO 9733513 Sep 1997 WO
WO 9735636 Oct 1997 WO
WO 9747236 Dec 1997 WO
WO 9826716 Jun 1998 WO
WO 9829030 Jul 1998 WO
WO 9926530 Jun 1999 WO
WO 9959460 Nov 1999 WO
WO 0016686 Mar 2000 WO
WO 03068047 Aug 2003 WO
WO 2004091719 Oct 2004 WO
WO 2006069215 Jun 2006 WO
Provisional Applications (1)
Number Date Country
60633063 Dec 2004 US